Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | ITGB1 | P05556 | 12/20 | 0.65 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.61 |
| ▸ | ITGAV | P06756 | 9/20 | 0.61 |
| ▸ | ITGA5 | P08648 | 9/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.61 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.52 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16378072 | 0.89 | ITGB1 (0.66) | L3MBTL1ITGB1ITGA4ITGB3ITGAV | |
| SCHEMBL13927753 | 0.88 | L3MBTL1 (0.61) | L3MBTL1ITGB1ITGA4 | |
| SCHEMBL15145361 | 0.87 | L3MBTL1 (0.68) | L3MBTL1ITGB1ITGA4ITGB3ITGAV | |
| SCHEMBL4527614 | 0.85 | ITGB1 (0.62) | L3MBTL1ITGB1ITGA4ITGB3ITGAV | |
| SCHEMBL4188079 | 0.84 | ITGB1 (0.64) | L3MBTL1ITGB1ITGA4ITGB3ITGAV | |
| SCHEMBL8724859 | 0.84 | L3MBTL1 (0.63) | L3MBTL1KMT2AACEPTPN1 | |
| SCHEMBL8724861 | 0.84 | L3MBTL1 (0.63) | L3MBTL1KMT2AACEPTPN1 | |
| SCHEMBL4166643 | 0.83 | L3MBTL1 (0.63) | L3MBTL1ITGB1ITGA4KMT2AACE | |
| SCHEMBL21358870 | 0.82 | L3MBTL1 (0.54) | L3MBTL1ITGB1ITGA4ITGB3ITGAV | |
| SCHEMBL21358872 | 0.82 | L3MBTL1 (0.54) | L3MBTL1ITGB1ITGA4ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | TAS2R10, TAS2R50, TAS2R8 | L3MBTL1 4231/4885ITGB1 3033/4885ITGA4 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.